

Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1

MATTHEW C. RIDDLE, MD¹
DANIEL J. DRUCKER, MD²

Current therapies for type 2 diabetes are frequently associated with inadequate control of postprandial hyperglycemia, weight gain, and, in the case of oral agents, loss of efficacy over time. A better understanding of physiological responses to meals is leading to the development of new agents whose therapeutic action is based on the enhancement of gastrointestinal hormone action. These therapies are associated with slowing of gastric emptying, stimulation of insulin and inhibition of glucagon secretion, improved control of postprandial hyperglycemia, and control of body weight. This review summarizes several limitations in the treatment of type 2 diabetes and describes the mechanisms of action and clinical data obtained with amylin and glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of diabetes.

Despite considerable effort by patients and physicians, the results of treating type 2 diabetes are often disappointing. This review examines the limitations of current antihyperglycemic therapies and assesses the potential of the emerging class of agents that mimic or enhance the actions of amylin and GLP-1, which are both gastrointestinal peptide hormones that in concert with insulin and glucagon regulate fuel homeostasis and eating behavior (1–4). Several agents from this class have been recently approved for

clinical use or are in the advanced stages of development. Their mechanisms of action and therapeutic effects, as described in peer-reviewed publications, will be discussed.

BARRIERS TO NORMALIZING GLYCEMIA

The evidence-based target for glycemic control is an HbA_{1c} (A1C) $\leq 7\%$ (5), although several groups have proposed an A1C target of 6.5% based on epidemiological analyses (6,7). In clinical trials, patients have achieved A1C values near 7% using basal-bolus insulin treatment in type 1 (8) or type 2 (9) diabetes or combinations of oral treatments and insulin for type 2 diabetes (10). However, routinely maintaining glycemic control at $< 7\%$ remains an elusive goal in medical practice (11,12).

Several limitations of currently available antihyperglycemic medications are important barriers to diabetes management, and these will be discussed in detail in this review. Economic factors and limited access to providers experienced in managing diabetes are also important barriers, but the consideration of these is beyond the scope of this review.

Postprandial hyperglycemia

In the trials cited above (8–10), good control of fasting and between-meal glucose

levels was achieved, but postprandial glucose values remained high. Several agents have been developed specifically to reduce hyperglycemia after meals. α -Glucosidase inhibitors reduce postprandial hyperglycemia by limiting the digestion of complex carbohydrates in the upper small intestine, leading to delayed absorption from the distal small intestine (13,14). Use of these agents is associated with increased secretion of GLP-1, which may contribute to their therapeutic effects (15,16). The nonsulfonylurea secretagogues repaglinide and nateglinide provoke rapid secretion of endogenous insulin with meals (17,18). However, neither of these agents consistently eliminates postprandial glycemic increments. For example, Fig. 1 shows the patterns of plasma glucose and insulin during treatment with placebo, nateglinide, or a sustained-release form of the sulfonylurea glipizide after overnight normalization of fasting glucose by a basal insulin infusion (19,20). Nateglinide increased the postprandial insulin responses but did not completely control postprandial increments in glucose excursion. Even systematic use of rapid-acting analogs of insulin has yielded mixed results, with complete prevention of postprandial hyperglycemia rarely being achieved (21). In general, studies show that these agents reduce increments of glucose after meals by $\leq 50\%$. Residual postprandial hyperglycemia contributes to the abnormal glycemic exposure of tissues and limits efforts to reduce A1C from $\sim 7\%$ to the normal 4–6% range (22). Furthermore, both epidemiological evidence and physiological findings have led to the hypothesis that increments of glucose after meals may have harmful metabolic effects beyond simply contributing to glycosylation of proteins and may increase the risk of cardiovascular events (23). Interventional trials testing whether targeting postprandial hyperglycemia is effective in reducing medical outcomes will probably require methods of treatment that are more effective than those currently available.

Hypoglycemia

Hypoglycemia may occur during treatment with any insulin or oral secretagogue, especially when glycemic control

From the ¹Section of Diabetes, Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland, Oregon; and the ²Department of Medicine, Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Toronto, Canada.

Address correspondence and reprint requests to Daniel J. Drucker, Director, Banting and Best Diabetes Centre, University of Toronto, Toronto General Hospital, 200 Elizabeth St., MBRW4R-402, Toronto Ontario Canada M5G 2C4. E-mail: d.drucker@utoronto.ca.

Received for publication 7 July 2005 and accepted in revised form 7 November 2005.

D.J.D. is a consultant for Amylin, Bristol-Myers Squibb, ConjuChem, Merck, Lilly, Novartis, GlaxoSmithKline, Transition Therapeutics, and TRIAD and has received research support from Lilly, Merck, Novartis, and Novo Nordisk; M.C.R. is a consultant to Amylin, ConjuChem, GlaxoSmithKline, Lilly-Amylin, and SanofiAventis; has received grant or research support from Amylin, Lilly-Amylin, Pfizer, and SanofiAventis; and has received honoraria from Amylin, SanofiAventis, and Novo Nordisk. M.C.R. does not own stock or equity in any of these companies.

Abbreviations: CNS, central nervous system; DPP-IV, dipeptidyl peptidase IV; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; RAMP, receptor activity-modifying protein.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2006 by the American Diabetes Association.




Figure 1—Persistence of postprandial hyperglycemia during treatment with a rapid- or long-acting secretagogue. Shown are daytime profiles of glucose (A) and insulin (B) in type 2 diabetes during ongoing treatment with placebo before each meal (\circ , dashed line), extended-release glipizide (average dose 10 mg) before breakfast (Δ), or nateglinide 120 mg before each meal (\blacktriangle). The same 15 patients were studied for each treatment. For clarity, an additional study in which twice-daily conventional glipizide was given was omitted from this figure. On the night before each study, subjects received an intravenous infusion of regular insulin to standardize fasting glucose levels. Neither secretagogue greatly reduced the increments of glucose after meals. Adapted with permission from Carroll et al. (20).

approaches normal levels. Intensively treated type 1 diabetic patients in the Diabetes Control and Complications Trial collectively experienced assistance-requiring hypoglycemia at a rate of 0.61 events per patient-year (i.e., more than one event every 6 months) (24). These events increased markedly at A1C levels $<7\%$ (24). Similarly, in the U.K. Prospective Diabetes Study, major hypoglycemia occurred in 2.3% of insulin-treated patients yearly (25). Although long-term metabolic injury from hypoglycemia is not well proven, acute hypoglycemia can cause motor vehicle accidents or other types of injuries, and fear of hypoglycemia may limit the willingness of both patients and physicians to intensify treatment (26).

Weight gain

Metformin and α -glucosidase inhibitors do not cause weight gain, but insulin,

secretagogues, and thiazolidinediones are all associated with variable degrees of weight gain. The excess weight gain with intensive versus standard insulin treatment of type 1 diabetes in the Diabetes Control and Complications Trial was ~ 2.1 kg in the first year and 4.8 kg after a mean follow-up period of 6.5 years (27). A susceptible subgroup gained much more weight and had worrisome increases in cardiovascular risk factors (28). In the U.K. Prospective Diabetes Study, treatment with insulin or a sulfonylurea was associated with significantly more weight gain over 10 years than treatment with metformin or diet alone (25,29). Weight gain with thiazolidinediones in large trials ranges from 2 to 5 kg (30,31).

Intensively treating type 2 diabetes with multiple injections of insulin can cause as much as 8 kg of weight gain (32), but this effect can be greatly reduced by concurrent treatment with metformin

(33,34). When hypoglycemia occurs or is suspected, patients may eat defensively to avoid or treat symptoms of hypoglycemia, so that some of the weight gain during insulin treatment may result from this behavior. Awareness of these difficulties may influence both patients and physicians to delay starting insulin therapy and avoid more aggressive adjustment of insulin dosage.

FASTING VERSUS PRANDIAL MECHANISMS OF CONTROLLING BLOOD GLUCOSE

The persistence of postprandial hyperglycemia, together with the hypoglycemia and weight gain accompanying efforts to use insulin for better control of postprandial glycemia, have engendered renewed interest in the prandial physiology of glucose homeostasis. The traditional description of diabetes focuses on abnormalities of insulin secretion and insulin action (35,36). This model is most accurate in the fasted state, when plasma glucose levels are determined mainly by insulin concentrations and hepatic sensitivity to insulin (37–39). Glucose uptake in the periphery during fasting occurs mainly in tissues not requiring insulin for entry of glucose into cells, especially the brain, and the relatively low concentrations of insulin during fasting contribute little to the clearance of glucose by other tissues (40). However, modest increases of systemic insulin concentrations can suppress free fatty acid mobilization from adipose tissue and thereby increase hepatic sensitivity to portal insulin. Also, concentrations of insulin are higher in portal than in systemic plasma, and the liver may be more sensitive than muscle to the effects of insulin (41,42). Modulation of insulin secretion during fasting consequently regulates hepatic glucose production and thus the concentration of glucose in plasma. Small changes in plasma glucagon also modulate hepatic glucose production, in effect by altering hepatic responses at given levels of insulin (43,44).

The mechanisms regulating plasma glucose after eating are more complicated (38,39,45,46). An ordinary meal contains 50–100 g of carbohydrate, which is 10–20 times the amount of glucose in the blood. Several factors beyond increasing insulin secretion in response to rising glucose levels combine to prevent the dramatic hyperglycemia that would otherwise occur after meals.




Figure 2—Illustration of the “incretin effect.” In this study, six healthy subjects received 50 g of oral glucose (●, solid line) or, on another occasion, an intravenous infusion of glucose (○, dashed line) to achieve the same profile of plasma glucose. Data for plasma glucose (A) and serum insulin (B) levels are shown. * $P < 0.05$ for greater levels of plasma insulin after oral administration of glucose compared with intravenous glucose. Data are means \pm SE. Adapted with permission from Nauck et al. (53).

Incretin effect on insulin secretion

Rapid and sustained secretion of insulin during and after eating is necessary to limit postprandial hyperglycemia (47). Insulin concentrations in the peripheral circulation increase very rapidly (by five-fold or more) with meals (48); this rapid increase in postprandial insulin secretion depends only partly on rising levels of plasma glucose. Over 65 years ago, it was postulated that additional gut-related factors (incretins) contribute to the control of postprandial glycemia (49); this hypothesis was later confirmed when a sensitive assay for insulin became available (50–52). Figure 2 illustrates the “incretin effect,” showing a two to three times greater secretion of insulin after oral administration of glucose compared with after intravenous administration, leading to the same profile of plasma glucose concentrations (53). More recently, two specific peptides, glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 have been shown to account for a substantial portion of the incretin effect (1,2).

Suppression of glucagon secretion

Basal secretion of glucagon produces basal levels that lie on the steep part of

the dose-response curve for its hepatic effects. Under normal conditions, orally administered glucose sharply reduces glucagon levels, and a mixed meal typically causes no change, a small decline, or a modest increase in glucagon (38,39,45,46,54–56). Thus the normal hormonal response to eating includes important coordinated changes in plasma levels of both insulin and glucagon. As a result, hepatic glucose production can decline by as much as 60%. Glucagon secretion appears partly regulated by intraislet factors, including endogenous insulin secretion (57), as well as by other neural and endocrine factors.

Neural mechanisms

Neural mechanisms influence the secretion of both insulin and glucagon (58,59). A long-recognized example is the “cephalic phase” of insulin secretion (47,60). A very early increase of insulin secretion occurs before food is swallowed, provoked by visual, olfactory, or oral mechanisms leading to efferent neural signals to the islets. A quantitatively more important process involving neural regulation is the effect that rising concentrations of plasma glucose have on the efficiency of

glucose production and uptake by tissues, independent of islet hormones (61,62). Glucose sensors in the portal vein or elsewhere transmit signals to areas in the central nervous system (CNS) that in turn send efferent signals to the liver, muscle, and probably other tissues (63,64). The delivery of gastric contents to the small intestine is at least partially neurally regulated, and variations in the rate of delivery contribute importantly to peak postprandial glucose levels (65). Plasma glucose levels affect gastric emptying, with hyperglycemia generally associated with slower emptying in healthy persons (66).

Abnormalities of prandial responses

As described above, a complex integrated process involving increased secretion of insulin, reduced secretion of glucagon, slowing of gastric emptying, and neural regulation of various tissues normally limits the rise in plasma glucose levels after meals. Many components of this prandial response are abnormal in individuals with diabetes or impaired glucose tolerance. Prandial insulin secretion is absent in type 1 diabetes and delayed and reduced in type 2 diabetes. In type 2 diabetes, both direct glucose-induced insulin secretion (67,68) and incretin-mediated potentiation of insulin secretion are reduced (69). The incretin effect may also be diminished in some patients with early type 1 diabetes (70). Glucagon secretion is typically high during fasting and is not suppressed by an oral glucose challenge, and it increases more than normal after a mixed meal in diabetic individuals (44,55,57,71,72). Uptake of absorbed glucose by the liver may be reduced, and suppression of endogenous glucose production is markedly impaired (46,55,73). Clearance of glucose entering the systemic circulation is also reduced (73). The impaired ability of hyperglycemia itself to regulate glucose production and clearance contributes to these abnormalities (74,75). Gastric emptying is slowed in patients with diabetic gastroparesis, but early in the course of diabetes emptying may be more rapid than normal (76). These changes all contribute to a failure of postprandial glucose regulation. Figure 3 illustrates some of the most important abnormalities after a glucose challenge in type 2 diabetes (55).

These abnormalities are not entirely corrected by exogenous insulin (77–79). For example, Fig. 4 illustrates an early study in which a high-carbohydrate meal




Figure 3—Profiles of glucose (A), insulin (B), and glucagon (C) after an oral glucose load (\downarrow) in 10 healthy (\circ , dashed line) and 10 type 2 diabetic (\bullet , solid line) subjects. An excessive and prolonged increase of plasma glucose, delayed and reduced response of insulin, and lack of suppression of glucagon are apparent in the diabetic subjects. Data are means \pm SE. Adapted with permission from Mitrakou et al. (55).

was given to type 2 diabetic patients (77). An intravenous insulin infusion that produced very high plasma concentrations of insulin with appropriate timing after the meal improved the postprandial hyperglycemia only moderately, and the abnormal postprandial increase of glucagon was not altered. Furthermore, the difficulty with weight gain experienced by

most patients with type 2 diabetes and some with type 1 diabetes may be related to abnormalities that are also not corrected by administration of insulin. Recent data illustrate the importance of multiple gastrointestinal peptide hormones for the integrated control of gut motility, satiety, and postprandial islet hormone responses in individuals with

normal glycemic regulation and in those with diabetes.

GASTROINTESTINAL PEPTIDES AFFECTING POSTPRANDIAL GLYCEMIC CONTROL

Amylin

Islet amyloid polypeptide, or amylin, was originally identified as a major constituent of pancreatic amyloid deposits and subsequently shown to be a 37-amino acid peptide cosecreted together with insulin from islet β -cells. Amylin is derived from a larger 89-amino acid preproamylin precursor, and amylin immunoreactivity and mRNA are also present in islet somatostatin-producing δ -cells; in the lung, stomach, duodenum, jejunum, ileum, colon, and rectum; and throughout the CNS (80). Mature bioactive amylin undergoes posttranslational modifications essential for bioactivity, including formation of an intramolecular disulfide bond and COOH-terminal amidation (80). Circulating amylin also exists in nonglycosylated and glycosylated forms in normal and diabetic human subjects.

Plasma levels of amylin increase in response to nutritional stimuli; islet β -cells appear to be the predominant source of circulating amylin (80). Amylin secretion is also stimulated by glucagon, GLP-1,




Figure 4—Profiles of glucose, insulin, and glucagon after a diabetic patient ate a carbohydrate (CHO) meal. A study without (\circ) and one with (\bullet) an intravenous infusion of insulin for 1 h during and after the meal are shown. Adapted with permission from Unger (77).

and cholinergic agonists and is inhibited by somatostatin and insulin.

Amylin-binding sites have been detected in pancreatic β -cells, skeletal muscle, kidney, lung, and brain (81). Functional amylin receptors are generated by coexpression of the G-protein-coupled calcitonin receptor gene and receptor activity-modifying proteins (RAMPs) (82). The potential for the combination of calcitonin receptor isoforms and different RAMP proteins gives rise to at least six different subtypes of amylin receptors that display unique pharmacological properties (83). RAMP-1 and -3 mRNAs are colocalized with calcitonin receptor gene mRNA in mouse pancreatic β -cells (84).

The acute glucoregulatory actions of exogenous amylin include inhibition of gastric emptying and glucagon secretion, with sustained amylin administration leading to reduced food intake and weight loss (4). Amylin potently inhibits glucagon secretion, and reduction of amylin activity using anti-amylin antiserum has been shown to dose-dependently increase arginine-stimulated insulin, glucagon, and somatostatin secretion from isolated rat islets, linking endogenous intraislet amylin to inhibitory effects on pancreatic β -, α -, and δ -cells (85). Antagonism of amylin activity has no effect on insulin levels under basal conditions but significantly augments glucose-stimulated insulin secretion in normal but not in diabetic subjects (86).

Exogenous amylin inhibits gastric emptying and gastric acid secretion and reduces short-term food intake. Furthermore, chronic peripheral or intracerebroventricular infusion of amylin reduces food intake, leading to weight loss in rats (87,88). Conversely, amylin $-/-$ mice exhibit increased body weight relative to control mice, and chronic inhibition of central amylin signaling increases food intake and total fat mass in rats (89). Hence endogenous amylin contributes to the long-term control of satiety and body weight.

Amylin $-/-$ mice are healthy and exhibit enhanced glucose clearance and increased sensitivity to the diabetogenic effects of alloxan (90). The physiological importance of the satiety effect of amylin is reflected by enhanced weight gain of amylin $-/-$ mice, which also exhibit reduced responsiveness to the anorectic actions of exogenous cholecystokinin and bombesin (91). Amylin also exerts an inhibitory effect on bone resorption, and

amylin $-/-$ mice exhibit reduced bone mass, increased numbers of osteoclasts, and increased rates of bone resorption (92).

GIP

GIP is a 42-amino acid peptide produced in the duodenum in enteroendocrine K cells. GIP contains an alanine residue at position 2 and is a physiological substrate for the enzyme dipeptidyl peptidase IV (DPP-IV) (93), which clips and inactivates full-length GIP, thereby generating inactive GIP(3–42). GIP is secreted after nutrient ingestion, functions predominantly as an incretin, and enhances glucose-dependent insulin secretion (94). The actions of GIP are transduced via a seven-transmembrane G protein-coupled receptor predominantly expressed in islet β -cells and to a lesser extent in peripheral sites such as adipose tissue and bone (95). Consistent with the known actions of GIP, blockade of GIP action reduces insulin secretion in rodents (96,97), and genetic elimination of the GIP receptor leads to mild glucose intolerance after enteral glucose loading in mice (98). Most GIP actions in normal or diabetic rodents have been elucidated in short-term studies of GIP administration, and little information is available on the consequences of repeated or continuous GIP administration in experimental models of diabetes. In an intriguing finding, GIP receptor $-/-$ mice exhibit decreased adipose tissue mass, improved insulin sensitivity, and resistance to diet-induced obesity (99). Furthermore, treatment of diabetic *ob/ob* mice with a GIP receptor antagonist markedly attenuates diabetes over an 11-day period, which illustrates the potential importance of GIP receptors on adipocytes for the control of insulin sensitivity (100).

Although GIP exerts potent stimulatory effects on insulin secretion in normal rodents and human β -cells, the diabetic β -cell is relatively resistant to GIP action (101). The mechanisms underlying the markedly diminished GIP responsiveness in experimental or clinical diabetes are not completely understood (102) but may involve downregulation of GIP receptor expression (103) or receptor desensitization. Hence the available data suggest that continuous administration of GIP receptor agonists alone may be submaximally effective for the treatment of type 2 diabetes (102). However, whether the GIP-resistant diabetic β -cell might recover GIP responsiveness after treatment with GLP-1R ago-

nists or DPP-IV inhibitors remains to be determined.

GLP-1

GLP-1 is a 30-amino acid gut peptide produced in enteroendocrine L cells located in the distal ileum and colon. GLP-1 is rapidly secreted from the distal gut within minutes of food being ingested. GLP-1 secretion is controlled through a combination of neural and endocrine stimulatory factors that promote initial rapid GLP-1 release. Subsequent direct nutrient contact with GLP-1-secreting L cells in the distal small bowel and colon (104) also stimulates GLP-1 secretion. GLP-1 also contains an NH_2 -terminal alanine at position 2, rendering it a substrate for cleavage by DPP-IV (105). Both enzymatic inactivation and renal clearance contribute to a very short circulating $t_{1/2}$ of several minutes for native GLP-1 (106). DPP-IV activation results in the inactivation of GLP-1(7–36) amide and the generation of the metabolite GLP-1(9–36) amide, which does not activate the GLP-1 receptor (107).

GLP-1 controls blood glucose via multiple actions, principally stimulation of insulin secretion and inhibition of both glucagon secretion and gastric emptying (1). GLP-1 also activates regions in the CNS important for control of satiety (108). Hence short-term administration of intracerebroventricular or peripheral GLP-1R agonists reduces food intake, whereas chronic GLP-1R agonist administration has produced weight loss in preclinical studies (109). Moreover, even larger GLP-1R agonists that do not readily cross the blood-brain barrier are able to signal the CNS and promote satiety and weight loss (110), consistent with the importance of ascending vagal afferents for transmission of the GLP-1R signal. GLP-1 also promotes expansion of β -cell mass via stimulation of β -cell proliferation and inhibition of apoptosis (111,112) in multiple preclinical models of experimental diabetes (1). The cytoprotective actions of GLP-1R agonists have also been observed in human islets cultured in vitro (113, 114).

GLP-1 exerts extrapancreatic actions independent of effects on glucoregulation, including activation of the hypothalamic-pituitary axis and induction of an aversive stress response in rodents (115,116). Moreover, GLP-1R agonists enhance learning and memory and promote neuronal survival in experimental models of neurotoxicity (117,118). Fur-

thermore, short-term GLP-1 administration activates cytoprotective pathways in vulnerable cardiomyocytes (119) and improves myocardial contractility in pre-clinical studies (120) and in human subjects after myocardial infarction and revascularization (121).

The physiological roles of endogenous GLP-1 have been identified in studies that have interrupted GLP-1 action using immunoneutralizing antisera, the GLP-1R antagonist exendin(9–39), and GLP-1 receptor $-/-$ mice. These experiments have determined that GLP-1 is essential for control of both fasting and postprandial glucose in rodents (122) and human subjects (123,124). Furthermore, blockade of GLP-1 action results in reduced insulin and increased glucagon secretion, disruption of signals emanating from the portal glucose sensor, as well as an increased rate of gastric emptying (125,126). The actions of GLP-1 are also essential for control of β -cell mass, as GLP-1R $-/-$ mice exhibit a reduced number of large islets (127) and enhanced susceptibility to apoptotic β -cell death (112).

DPP-IV

The observation that both GIP and GLP-1 are rapidly degraded by the action of DPP-IV (93) has fostered interest in determining the role of this enzyme in glucose homeostasis. DPP-IV inhibitors lower blood glucose in normal animals as well as in experimental models of diabetes (2,128–130). DPP-IV inhibition also improves glucose control, reduces A1C, and enhances insulin action in experimental models of diabetes but has no effect on satiety or body weight regulation (131–135). Treating diabetic rodents with DPP-IV inhibitors improves islet survival and maintains β -cell mass and islet function (136,137).

Conversely, genetic inactivation of the DPP-IV gene results in mice with improved glucose tolerance in association with increased levels of GIP and GLP-1 and enhanced insulin secretion after glucose loading (138). Similarly, rats with a naturally occurring inactivating mutation in the DPP-IV gene exhibit enhanced glucose-stimulated insulin secretion and improved glucose clearance (139). Moreover, rats and mice with DPP-IV gene mutations exhibit resistance to diet-induced obesity (140,141). Hence the DPP-IV gene is an essential determinant regulating incretin degradation and the control of glucose-stimulated insulin secretion in

rodents. Although the precise substrates important for DPP-IV action in diabetic human subjects remain unclear, disruption of GLP-1 and GIP receptors in mice completely eliminates the glucose-lowering properties of DPP-IV inhibitors (142).

AMYLIN AND GLP-1 ACTION IN NORMAL AND DIABETIC HUMAN SUBJECTS

Amylin

Plasma levels of endogenous circulating amylin in healthy humans correlate with levels of insulin, are lower in the fasted state (~ 4 – 8 pmol/l), and rise to 15 – 25 pmol/l after meal ingestion (143). The kidney is an important determinant of amylin clearance, and human subjects with renal failure exhibit increased circulating levels of plasma amylin (144). Type 1 diabetes is an amylin-deficient state (143), whereas amylin levels are often elevated in patients with impaired glucose tolerance, insulin-resistant obesity, and type 2 diabetes (145).

The potential for native human amylin to form amyloid fibrils prompted the development of synthetic amylin analogs resistant to fibril formation. Pramlintide has three amino acid substitutions at positions 25, 28, and 29 that do not impair the biological potency of the molecule. Pramlintide lowers meal-related glucose excursions in normal subjects and in patients with type 1 and type 2 diabetes (4). In contrast, pramlintide has little effect on blood glucose levels in subjects with type 1 diabetes after intravenous glucose administration (146). The acute glucose-lowering actions of pramlintide are dependent on the inhibition of gastric emptying and suppression of the abnormal postprandial rise in circulating glucagon levels in diabetic subjects (147,148). Conversely, repeated administration of pramlintide does not impair the counter-regulatory response to insulin-induced hypoglycemia in normal or diabetic human subjects (149,150).

GLP-1

Acute infusion or subcutaneous administration of native GLP-1(7–36) amide or GLP-1(7–37) lowers meal-related glucose excursions in human subjects via inhibition of gastric emptying and glucagon secretion and potentiation of glucose-dependent insulin secretion (1,2). GLP-1 has also been found in short-term studies of normal and diabetic subjects to en-

hance satiety and reduce food intake (151). Although acute (5-day) administration of GLP-1 produces weight loss in healthy obese subjects (152), from short-term studies it appears that GLP-1R agonists do not increase energy expenditure in normal (153) or diabetic (154) human subjects.

Repeated daily injections (155) or continuous subcutaneous administration of native GLP-1 lowers blood glucose in subjects with type 2 diabetes (156,157). In one study, continuous infusion of GLP-1 for 6 weeks produced significant improvements in fasting and postprandial glucose and A1C in association with increases in insulin sensitivity and a reduction in body weight (156). Nevertheless, because most of GLP-1 is rapidly degraded after exogenous administration (106), pharmaceutical strategies for enhancing GLP-1 action in human diabetic patients has focused on developing degradation-resistant GLP-1R agonists or potentiating endogenous levels of circulating GLP-1 via inhibition of DPP-IV activity (1,2,130).

Exenatide (exendin-4) is a 39-amino acid synthetic GLP-1R agonist that has been shown in preclinical and clinical studies to mimic the entire spectrum of GLP-1R-dependent actions. Exendin-4 was originally isolated from the venom of a lizard, *Heloderma suspectum* (158). It is encoded by a distinct gene not present in the human genome (159); the corresponding residues of exendin-4 exhibit 53% amino acid identity relative to the 30-amino acid human GLP-1 sequence. Exendin-4 contains a glycine at position 2, is resistant to DPP-IV cleavage, and is considerably more potent than native GLP-1 in vivo due in large part to less rapid inactivation and clearance (109). Dosing range studies have identified an optimal glucose-lowering dose range of 0.05 – 0.2 $\mu\text{g}/\text{kg}$ for exenatide when injected subcutaneously in human diabetic subjects (160). Current antidiabetic regimens for exenatide administration involve twice-daily dosing. However, an injectable long-acting release preparation suitable for weekly dosing, exenatide LAR (161), is under clinical development.

Liraglutide is an acylated human GLP-1 analog that has completed phase 2 clinical trials. Liraglutide binds noncovalently to albumin, may be administered once daily, and exhibits a more prolonged pharmacokinetic profile (162) relative to native GLP-1 or exenatide (154,163). Other albumin-based GLP-1R agonists

Table 1—Contrasting and overlapping actions of GLP-1R and amylin agonists and DPP-IV inhibitors

	Amylin agonists	GLP-1R agonists	DPP-IV inhibitors
Enhance insulin secretion	–	+	+
Inhibit glucagon secretion	+	+	+
Slow gastric emptying	+	+	–
Induce satiety and weight loss	+	+	–
Improve β -cell function	–	+	+

under investigation include CJC-1131, a DPP-IV-resistant GLP-1 analog modified with a reactive chemical linker that forms a covalent bond with a single amino acid residue within human serum albumin (164), and Albugon, a recombinant albumin/GLP-1 hybrid protein (110). The ability to link a GLP-1 peptide domain conferring GLP-1R activation to albumin or other proteins that exhibit a more prolonged circulating $t_{1/2}$ should enable the development of longer-acting GLP-1R agonists suitable for once daily or even weekly administration.

DRUGS APPROVED OR IN LATE STAGES OF CLINICAL DEVELOPMENT

The effects of various agents targeting these gastrointestinal peptide systems, as shown in preclinical studies, are compared in Table 1. Enough experience from large clinical trials has been obtained to permit a preliminary assessment of the clinical potential of several specific agents. Pramlintide and exenatide have been approved for clinical use in the U.S., and the GLP-1R agonist liraglutide and the DPP-IV inhibitors vildagliptin and sitagliptin are well along in clinical development.

Pramlintide

The amylin analog pramlintide (Symlin) has been approved for treatment of type 1 and insulin-requiring type 2 diabetes. When injected 15 min before a meal, it slows gastric emptying, suppresses plasma levels of glucagon, increases satiety, and blunts postprandial hyperglycemia (165). Pramlintide also reduces

appetite in diabetic and obese nondiabetic human subjects (166). Appropriate doses for pramlintide administration have been determined in clinical studies: 15 μ g before major meals, increased slowly to 60 μ g for type 1 diabetes, and 60 μ g before major meals, later increased to 120 μ g for type 2 diabetes (167–169). Slow titration to the full dose over ≥ 4 weeks can reduce nausea, vomiting, and insulin-induced hypoglycemia, the drug's main side effects. Reduction of prandial insulin dosage by 50% is advised to minimize the risk of hypoglycemia after initiation of pramlintide therapy.

Published results from four 52-week trials examining the efficacy of pramlintide therapy are available, two in type 1 and two in type 2 diabetes (170–173). In the two trials in type 1 diabetic subjects (170,171), treatment with pramlintide 60 μ g q.i.d. with meals led to modest, placebo-adjusted reductions of A1C (0.27 and 0.30%, respectively) at study end point. Significant placebo-adjusted reductions

of weight also occurred (1.5 and 1.2 kg). In insulin-requiring type 2 diabetes, treatment with pramlintide 150 μ g t.i.d. or 120 μ g b.i.d. resulted in similar placebo-adjusted A1C reductions (0.44 and 0.40%, respectively) and placebo-adjusted weight reductions (2.5 and 2.1 kg). Patients with both type 1 and type 2 diabetes reported nausea about twice as frequently with pramlintide as with placebo, although this problem declined markedly with time. In one of the type 1 trials, a worrisome increase in severe hypoglycemia occurred with pramlintide in the first weeks after treatment was begun (171). However, in these trials pramlintide was not started at a lower dose and then increased, and prandial insulin doses were not decreased with commencement of pramlintide therapy.

Figure 5A shows the results of a study of 40 patients with type 1 diabetes taking usual dosages of regular insulin with or without pramlintide before a meal (174). In this research setting, pramlintide en-




Figure 5—A: Plasma glucose increments after a meal in 19 subjects with type 1 diabetes taking regular insulin alone (\circ , dashed line) or with 60 μ g pramlintide (\bullet , solid line) before the meal. **B:** Glycemic responses to a meal in patients with type 2 diabetes treated with placebo ($n = 23$; \circ) or exenatide 10 μ g ($n = 27$; \bullet) along with metformin and a sulfonylurea. Data are means \pm SE. Adapted with permission from Weyer et al. (174) and Kendall et al. (178).

tirely prevented the postprandial hyperglycemia ordinarily seen in subjects with type 1 diabetes. However, these profiles illustrate how strongly pramlintide can accentuate the effects of prandial insulin, making early postprandial hypoglycemia easily possible if the insulin dose is not decreased appropriately.

Exenatide

Exenatide (Byetta), a GLP-1 receptor agonist, has been approved for use in patients with type 2 diabetes who exhibit unacceptable glycemic control while using metformin and/or a sulfonylurea. Exenatide shares several clinical features with pramlintide despite binding to different receptors. Exenatide slows gastric emptying, suppresses glucagon, and promotes satiety. In addition, it potentiates nutrient-stimulated insulin secretion (175). Studies have defined an appropriate dosing strategy: 5 μg injected twice daily for the first month, followed by 10 μg twice daily thereafter (175–178). Nausea and vomiting can occur, especially at the beginning of treatment, but this is less frequent when treatment is started with the 5- μg dose.

Published results from three large 6-month trials testing the addition of exenatide to metformin alone, sulfonylurea alone, or metformin and a sulfonylurea together are available (176–178). The placebo-adjusted decline of A1C from baseline levels of 8.2–8.6% was $\sim 1.0\%$ in each trial. A mean placebo-adjusted weight loss of 2.5 kg occurred when exenatide was added to metformin, 1.0 kg when the drug was added to a sulfonylurea, and 0.9 kg when it was added to metformin plus a sulfonylurea. As with pramlintide, initiation of exenatide resulted in at least a doubling of the incidence of nausea compared with placebo. Severe hypoglycemia was uncommon, but mild-to-moderate hypoglycemia increased initially when exenatide was added to a sulfonylurea (177,178).

Exenatide therapy has been compared with insulin glargine in patients failing to achieve optimal glycemia control on metformin and a sulfonylurea. After 26 weeks of therapy, the mean A1C reduction (1.1%) was comparable in both groups (179). The incidence of gastrointestinal side effects and the dropout rate was higher in the exenatide-treated patients. However, patients treated with insulin glargine experienced a mean weight gain of 1.8 kg, whereas exenatide-treated




Figure 6—A: Plasma glucose profiles over 24 h in 13 subjects with type 2 diabetes after 1 week of treatment with placebo (○, broken line) or liraglutide (●, solid line). B: Plasma glucose profiles over 24 h after 4 weeks of treatment in type 2 diabetic patients treated with placebo (n = 19; ○, broken line) or vildagliptin 100 mg/day (n = 18; ●, solid line). The timing of meals is shown by arrows. Adapted with permission from Degn et al. (180) and Ahren et al. (182).

subjects had a mean weight loss of 2.3 kg. Rates of reported hypoglycemia were similar in the different treatment groups (179).

Figure 5B shows glucose profiles after a standard meal in a subset of patients from the trial in which exenatide was added to metformin and a sulfonylurea (178). Although fasting glucose was reduced by ~ 25 mg/dl with the 10- μg dose of exenatide, the more dramatic effect was the $\sim 90\%$ reduction of the incremental glycemic area compared with that found with placebo.

Liraglutide

Liraglutide (NN2211) is a GLP-1 receptor agonist that is administered by a single daily injection. As with pramlintide and exenatide, nausea is the most common adverse effect associated with liraglutide administration. Although the optimal dose has not yet been identified, a 12-

week trial including 193 patients with type 2 diabetes showed that 0.75 mg liraglutide daily caused equivalent placebo-adjusted reductions of A1C compared with the sulfonylurea glimepiride (0.75 and 0.74%) from mean baseline values of 7.4–7.9% (163). However, liraglutide treatment was associated with a placebo-adjusted weight reduction of 0.39 kg, whereas patients treated with glimepiride experienced a mean weight gain of 0.94 kg.

The 24-h glycemic profile of 13 patients treated with placebo or liraglutide 6 $\mu\text{g}/\text{kg}$ (~ 0.6 mg) for 1 week is shown in Fig. 6A (180). Most of the reduction in the profile consisted of lower basal and preprandial values, with only a small reduction of postprandial increments. A significant reduction of the glucagon profile occurred as well, but insulin levels were not different between treatments (180).

Table 2—Summary of study findings with pramlintide, exenatide, liraglutide, and vildagliptin

	Treatment maximum dosage	Type of diabetes	Other treatment	n	Duration (weeks)	Baseline A1C (%)	Placebo-adjusted Δ A1C (%)	Baseline BMI (kg/m ²)	Placebo-adjusted Δ weight (kg)
Whitehouse 2002	Pramlintide 60 μ g q.i.d.	Type 1	Insulin	480	52	8.7–8.9	–0.27	25.2–25.8	–1.5
Ratner 2004	Pramlintide 60 μ g q.i.d.	Type 1	Insulin	651	52	8.9	–0.30	26.3–26.8	–1.2
Ratner 2002	Pramlintide 150 μ g t.i.d.	Type 2	Insulin	538	52	9.2	–0.44	30.1–30.4	–2.5
Hollander 2003	Pramlintide 120 μ g b.i.d.	Type 2	Insulin	656	52	9.1	–0.40	34	–2.1
DeFronzo 2005	Exenatide 10 μ g b.i.d.	Type 2	Metformin	272	30	8.2	–0.9	34.2	–2.5
Buse 2004	Exenatide 10 μ g b.i.d.	Type 2	Sulfonylurea	377	30	8.6	–0.98	33	–1.0
Kendall 2005	Exenatide 10 μ g b.i.d.	Type 2	Metformin/ sulfonylurea	733	30	8.5	–1.0	33.6	–0.9
Madsbad 2004	Liraglutide 0.75 mg once	Type 2	Diet	193	12	7.6	–0.75	30.3–31.9	–0.39
Ahren 2004	Vildagliptin 50 mg once	Type 2	Metformin	107	12	7.7–7.9	–0.7	29.4–30.2	–0

Vildagliptin

Vildagliptin (LAF237), an orally administered DPP-IV inhibitor, at a dosage of 50 mg/day was compared with placebo for 12 weeks in 107 patients with type 2 diabetes while the patients continued to take metformin (181). The placebo-adjusted reduction of A1C from mean baseline values of 7.8% was 0.7%. No significant between-treatment differences in change of weight occurred. Despite concern about the lack of specificity of vildagliptin's action, no notable safety issues emerged in this or other early trials.

The 24-h glycemic profiles of 37 patients treated for 4 weeks with vildagliptin 100 mg/day or placebo are shown in Fig. 6B (182). As was seen during treatment with liraglutide, vildagliptin treatment resulted in lower fasting and preprandial glucose values and modest reductions in postprandial increments. Insulin and glucagon profiles showed no change in the absolute levels of insulin but did show lower concentrations of glucagon (181, 182) after vildagliptin therapy. Furthermore, mathematical modeling studies have suggested that an improvement in β -cell function occurs after vildagliptin treatment (183,184).

POTENTIAL CLINICAL ROLES OF THESE AGENTS

The findings of the studies reviewed above are summarized in Table 2. Each of these agents causes clinically relevant reductions in A1C when starting from relatively low baseline values, with either no weight gain or a significant weight loss. In some cases, important effects on postprandial hyperglycemia have been shown. Because these candidate drugs address abnormalities of prandial physiology in diabetes that are inadequately treated by other therapies, they are all likely to contribute to the treatment of diabetes.

However, there is much more to learn about the optimal use and efficacy of these agents. The development of pramlintide was hampered by the lack of individualized reductions of insulin dose when the drug was added in early safety and efficacy trials, leading to some cases of severe insulin-induced hypoglycemia. Reducing the dosage of prandial insulin by 50% when pramlintide is started should greatly reduce the risk of hypoglycemia. However, more information is needed about which patients are most likely to benefit from the drug, how best to titrate pramlintide dosage to minimize nausea, and how to teach patients to adjust basal and prandial insulin doses during ongoing use of pramlintide. Studies documenting that excessive rates of severe nausea and severe hypoglycemia can be avoided during use of pramlintide in routine clinical practice are needed. At present, successful use of this agent appears to require an experienced physician and a highly motivated patient.

Exenatide is less likely to cause hypoglycemia if used by patients taking metformin, but the risk of hypoglycemia is significantly increased in patients treated with both exenatide and a sulfonylurea. The patient population that is most likely to respond well to exenatide has not yet been identified, and information as to whether twice daily fixed dosing is always optimal and how to individualize dose titration to minimize nausea has not yet been forthcoming. Whether concurrent treatment with secretagogues can be made safe by reducing the dosage of exenatide or the secretagogue or by using secretagogues least likely to cause hypoglycemia must be further established. Studies are needed to verify that these measures can limit the frequency of nausea and hypoglycemia in the same way

that experience has led to acceptable rates of side effects with metformin.

Similar practical concerns apply to liraglutide and vildagliptin. Because these agents are in an earlier stage of development, the optimal doses and extent of safety concerns are still unknown.

There are both similarities and differences among these agents that may influence their clinical applications. For example, although pramlintide and exenatide bind to separate receptors, their clinical effects have substantial overlap. Both can blunt or even abolish postprandial increments of glucose, and both more often cause weight loss than weight gain while improving glycemic control. These features directly contrast with the failings of prior therapies and indicate the potential for very effective use of these agents in combination regimens. However, the populations suited to each of these two agents are different: pramlintide has been approved for use only by patients already taking both basal and prandial insulin, and subsequently the risk of insulin-induced hypoglycemia when starting pramlintide appears significant. In contrast, exenatide is approved for use by type 2 diabetic patients not yet requiring insulin, so that the addition of exenatide to prior oral therapies promises a lower rate of hypoglycemia than that achieved with the addition of insulin.

Although liraglutide and vildagliptin enhance GLP-1 receptor occupancy in different ways, they also have similarities in their effects. Both reduce fasting and 24-h profiles of glucose effectively but have relatively less effect on postprandial increments than pramlintide or exenatide. This effect on basal glycemic control seems to depend more on a suppression of glucagon than potentiation of insulin secretion, although that must be present as well. In studies con-

ducted to date, they have differed in their effects on weight: liraglutide induces weight loss while improving glycemic control, like pramlintide and exenatide, whereas vildagliptin has not yet been shown to induce weight loss in clinical studies

The differences in actions of the three agents targeting the GLP-1 system highlight the limitations of our understanding of gastrointestinal peptide physiology. For example, it is still unclear to what extent the various effects of GLP-1 are mediated through actions directly on islet cells, the brain, or peripheral sites (e.g., intestinal mucosa, portal vein) and whether the differing effects of exenatide, liraglutide, and vildagliptin are due to differences in pharmacokinetics or mechanisms of action. Similar questions apply to amylin, which is currently thought to act mainly at the brain but which may have peripheral effects as well. Also it remains to be determined whether pramlintide might have different effects if delivered by a sustained-release formulation.

Scientific questions such as these are relevant to important clinical issues. What is the potential for long-term benefits or risks independent of glucose control and body weight with these new agents? Can the weight-loss benefits of pramlintide, exenatide, and liraglutide be sustained over time? Will these injectable peptides be associated with immunogenicity and the development of neutralizing antibodies that may diminish the efficacy of therapy over time in selected patients? Will there be cardiovascular benefits independent of the improvement in glycemic control with some or all of these agents? Will exenatide, liraglutide, and vildagliptin protect β -cells or promote their regeneration in clinical use, as appears to be the case in animal studies? Conversely, the recent description of hyperinsulinemic hypoglycemia and nesidioblastosis together with increased circulating levels of GLP-1 in a few patients after gastric bypass surgery further emphasizes the importance of understanding the long-term consequences of prolonged activation of the GLP-1 receptor in human subjects (185,186). The answers to these questions will determine, to a large extent, the future role of these agents in the treatment of type 2 diabetes.

Acknowledgments—This work was supported in part by operating grants from the Canadian Diabetes Association and the Juve-

nile Diabetes Research Foundation, a Canada Research Chair in Regulatory Peptides (to D.J.D.), and the Rose Hastings and Russell Standley Memorial Trusts (to M.C.R.).

References

- Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. *Diabetes Care* 26:2929–2940, 2003
- Deacon CF: Therapeutic strategies based on glucagon-like peptide 1. *Diabetes* 53: 2181–2189, 2004
- Vilsboll T, Holst JJ: Incretins, insulin secretion and type 2 diabetes mellitus. *Diabetologia* 47:357–366, 2004
- Schmitz O, Brock B, Rungby J: Amylin agonists: a novel approach in the treatment of diabetes. *Diabetes* 53 (Suppl. 3): S233–S238, 2004
- American Diabetes Association: Standards of medical care in diabetes. *Diabetes Care* 28 (Suppl. 1):S4–S35, 2005 [erratum in *Diabetes Care* 28:990, 2005]
- American Association of Clinical Endocrinologists: Consensus statement on guidelines for glycemic control. *Endocrine Practice* 8 (Suppl. 1):5–11, 2002
- A desktop guide to type 2 diabetes mellitus: European Diabetes Policy Group. *Diabet Med* 16:716–730, 1999
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. *N Engl J Med* 329: 977–986, 1993
- Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care* 23 (Suppl 2.):B21–B29, 2000
- Riddle MC, Rosenstock J, Gerich J: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. *Diabetes Care* 26:3080–3086, 2003
- Saydah SH, Fradkin J, Cowie CC: Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. *JAMA* 291:335–342, 2004
- Brown JB, Nichols GA, Perry A: The burden of treatment failure in type 2 diabetes. *Diabetes Care* 27:1535–1540, 2004
- Lebovitz HE: alpha-Glucosidase inhibitors. *Endocrinol Metab Clin North Am* 26: 539–551, 1997
- van de Laar FA, Lucassen PL, Akkermans RP, van de Lisdonk EH, Rutten GE, van Weel C: α -Glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. *Diabetes Care* 28: 154–163, 2005
- Goke B, Herrmann C, Goke R, Fehmann HC, Berghofer P, Richter G, Arnold R: Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. *Eur J Clin Invest* 24 (Suppl. 3):25–30, 1994
- Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W: Glucagon-like peptide 1 (7–36 amide) secretion in response to luminal sucrose from the upper and lower gut: a study using alpha-glucosidase inhibition (acarbose). *Scand J Gastroenterol* 30:892–896, 1995
- Schmitz O, Lund S, Andersen PH, Jonler M, Porsken N: Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. *Diabetes Care* 25: 342–346, 2002
- Hollander PA, Schwartz SL, Gatlin MR, Haas SJ, Zheng H, Foley JE, Dunning BE: Importance of early insulin secretion: comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. *Diabetes Care* 24:983–988, 2001
- Carroll MF, Izard A, Riboni K, Burge MR, Schade DS: Control of postprandial hyperglycemia: optimal use of short-acting insulin secretagogues. *Diabetes Care* 25:2147–2152, 2002
- Carroll MF, Gutierrez A, Castro M, Tsewang D, Schade DS: Targeting postprandial hyperglycemia: a comparative study of insulinotropic agents in type 2 diabetes. *J Clin Endocrinol Metab* 88:5248–5254, 2003
- Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus: Multicenter Insulin Lispro Study Group. *Arch Intern Med* 157: 1249–1255, 1997
- Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA_{1c}. *Diabetes Care* 26:881–885, 2003
- Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? *Diabetes* 54:1–7, 2005
- The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. *Diabetes* 46:271–286, 1997
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33): UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 352:837–853, 1998
- Cryer PE: Hypoglycemia is the limiting factor in the management of diabetes.

- Diabetes Metab Res Rev* 15:42–46, 1999
27. Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial. *Diabetes Care* 24:1711–1721, 2001
 28. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD: Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT: Diabetes Control and Complications Trial. *JAMA* 280:140–146, 1998
 29. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. *Lancet* 352:854–865, 1998
 30. Yki-Jarvinen H: Thiazolidinediones. *N Engl J Med* 351:1106–1118, 2004
 31. Vasudevan AR, Balasubramanyam A: Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability. *Diabetes Technol Ther* 6:850–863, 2004
 32. Lindstrom T, Eriksson P, Olsson AG, Arnqvist HJ: Long-term improvement of glycemic control by insulin treatment in NIDDM patients with secondary failure. *Diabetes Care* 17:719–721, 1994
 33. Strowig SM, Aviles-Santa ML, Raskin P: Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes. *Diabetes Care* 25:1691–1698, 2002
 34. Wulffele MG, Kooy A, Lehert P, Bets D, Ogerop JC, Borger van der Burg B, Donker AJ, Stehouwer CD: Combination of insulin and metformin in the treatment of type 2 diabetes. *Diabetes Care* 25:2133–2140, 2002
 35. Polonsky KS, Sturis J, Bell GI: Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell to compensate for insulin resistance: Seminars in Medicine of the Beth Israel Hospital, Boston. *N Engl J Med* 334:777–783, 1996
 36. DeFronzo RA: Lilly Lecture 1987: The triumvirate: β -cell, muscle, liver: a collusion responsible for NIDDM. *Diabetes* 37:667–687, 1988
 37. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD: Basal hepatic glucose production is regulated by the portal vein insulin concentration. *Diabetes* 47:523–529, 1998
 38. Cherrington AD: Banting Lecture 1997: Control of glucose uptake and release by the liver in vivo. *Diabetes* 48:1198–1214, 1999
 39. Consoli A: Role of liver in pathophysiology of NIDDM. *Diabetes Care* 15:430–441, 1992
 40. Rizza RA, Mandarino LJ, Gerich JE: Dose-response characteristics for effects of insulin on production and utilization of glucose in man. *Am J Physiol* 240:E630–E639, 1981
 41. Rebrin K, Steil GM, Getty L, Bergman RN: Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. *Diabetes* 44:1038–1045, 1995
 42. Lewis GF, Zinman B, Groenewoud Y, Vranic M, Giacca A: Hepatic glucose production is regulated both by direct hepatic and extrahepatic effects of insulin in humans. *Diabetes* 45:454–462, 1996
 43. Myers SR, Diamond MP, Adkins-Marshall BA, Williams PE, Stinsen R, Cherrington AD: Effects of small changes in glucagon on glucose production during a euglycemic, hyperinsulinemic clamp. *Metabolism* 40:66–71, 1991
 44. Jiang G, Zhang BB: Glucagon and regulation of glucose metabolism. *Am J Physiol* 284:E671–E678, 2003
 45. Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. *N Engl J Med* 327:707–713, 1992
 46. Basu A, Shah P, Nielsen M, Basu R, Rizza RA: Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. *J Investig Med* 52:366–374, 2004
 47. Caumo A, Luzi L: First-phase insulin secretion: does it exist in real life? Considerations on shape and function. *Am J Physiol* 287:E371–E385, 2004
 48. Polonsky KS, Given BD, Van Cauter E: Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. *J Clin Invest* 81:442–448, 1988
 49. Loew ER, Gray JS, Ivy AC: Is a duodenal hormone involved in carbohydrate metabolism? *Am J Physiol* 270:659–663, 1940
 50. Elrick H, Stimmler L, Hlad CJ, Arai Y: Plasma insulin responses to oral and intravenous glucose administration. *J Clin Endocrinol Metab* 24:1076–1082, 1964
 51. McIntyre N, Holdsworth CD, Turner DS: Intestinal factors in the control of insulin secretion. *J Clin Endocrinol Metab* 25:1317–1324, 1965
 52. Perley MJ, Kipnis DM: Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. *J Clin Invest* 46:1954–1962, 1967
 53. Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W: Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. *J Clin Endocrinol Metab* 63:492–498, 1986
 54. Muller WA, Faloon GR, Aguilar-Parada E, Unger RH: Abnormal alpha-cell function in diabetes: response to carbohydrate and protein ingestion. *N Engl J Med* 283:109–115, 1970
 55. Mitrakou A, Kelley D, Veneman T, Jensen T, Pangburn T, Reilly J, Gerich J: Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM. *Diabetes* 39:1381–1390, 1990
 56. Butler PC, Rizza RA: Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. *Diabetes* 40:73–81, 1991
 57. Unger RH: Glucagon physiology and pathophysiology in the light of new advances. *Diabetologia* 28:574–578, 1985
 58. Woods SC, Porte D Jr: Neural control of the endocrine pancreas. *Physiol Rev* 54:596–619, 1974
 59. Ahren B: Autonomic regulation of islet hormone secretion: implications for health and disease. *Diabetologia* 43:393–410, 2000
 60. Ahren B, Holst JJ: The cephalic insulin response to meal ingestion in humans is dependent on both cholinergic and noncholinergic mechanisms and is important for postprandial glycemia. *Diabetes* 50:1030–1038, 2001
 61. Sacca L, Hendler R, Sherwin RS: Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones. *J Clin Endocrinol Metab* 47:1160–1163, 1978
 62. Bell PM, Firth RG, Rizza RA: Effects of hyperglycemia on glucose production and utilization in humans: measurement with [23 H]-, [33 H]-, and [61 C]glucose. *Diabetes* 35:642–648, 1986
 63. Adkins-Marshall B, Pagliassotti MJ, Asher JR, Connolly CC, Neal DW, Williams PE, Myers SR, Hendrick GK, Adkins RB Jr, Cherrington AD: Role of hepatic nerves in response of liver to intraportal glucose delivery in dogs. *Am J Physiol* 262:E679–E686, 1992
 64. Moore MC, Connolly CC, Cherrington AD: Autoregulation of hepatic glucose production. *Eur J Endocrinol* 138:240–248, 1998
 65. Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. *Diabetes Care* 24:371–381, 2001
 66. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW: Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. *Diabetologia* 36:857–862, 1993
 67. Pfeifer MA, Halter JB, Porte D Jr: Insulin secretion in diabetes mellitus. *Am J Med* 70:579–588, 1981
 68. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D: Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. *J Clin Invest* 74:1318–1328, 1984

69. Nauck M, Stockmann F, Ebert R, Creutzfeldt W: Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. *Diabetologia* 29:46–52, 1986
70. Greenbaum CJ, Prigeon RL, D'Alessio DA: Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. *Diabetes* 51:951–957, 2002
71. Lefebvre PJ, Luyckx AS: Glucagon and diabetes: a reappraisal. *Diabetologia* 16: 347–354, 1979
72. Unger RH, Orci L: The essential role of glucagon in the pathogenesis of diabetes mellitus. *Lancet* 1:14–16, 1975
73. Firth RG, Bell PM, Marsh HM, Hansen I, Rizza RA: Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus: role of hepatic and extrahepatic tissues. *J Clin Invest* 77:1525–1532, 1986
74. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L: Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. *J Clin Invest* 102:744–753, 1998
75. Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, Rizza RA: Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. *Diabetes* 46:421–432, 1997
76. Phillips WT, Schwartz JG, McMahan CA: Rapid gastric emptying in patients with early non-insulin-dependent diabetes mellitus. *N Engl J Med* 324:130–131, 1991
77. Unger RH: Glucagon physiology and pathophysiology. *N Engl J Med* 285:443–449, 1971
78. Raskin P, Aydin I, Yamamoto T, Unger RH: Abnormal alpha cell function in human diabetes: the response to oral protein. *Am J Med* 64:988–997, 1978
79. Raskin P, Aydin I, Unger RH: Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. *Diabetes* 25:227–229, 1976
80. Cooper GJS: Amylin compared with calcitonin gene-related peptide: structure, biology and relevance to metabolic disease. *Endocr Rev* 15:163–201, 1994
81. Muff R, Born W, Fischer JA: Adrenomedullin and related peptides: receptors and accessory proteins. *Peptides* 22: 1765–1772, 2001
82. Christopoulos A, Christopoulos G, Morfis M, Udawela M, Laburthe M, Couvineau A, Kuwasako K, Tilakaratne N, Sexton PM: Novel receptor partners and function of receptor activity-modifying proteins. *J Biol Chem* 278:3293–3297, 2003
83. Hay DL, Christopoulos G, Christopoulos A, Sexton PM: Amylin receptors: molecular composition and pharmacology. *Biochem Soc Trans* 32:865–867, 2004
84. Martinez A, Kapas S, Miller MJ, Ward Y, Cuttitta F: Coexpression of receptors for adrenomedullin, calcitonin gene-related peptide, and amylin in pancreatic beta-cells. *Endocrinology* 141:406–411, 2000
85. Wang F, Adrian TE, Westermark GT, Ding X, Gasslander T, Permert J: Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. *Am J Physiol* 276:E19–E24, 1999
86. Mather KJ, Paradisi G, Leaming R, Hook G, Steinberg HO, Fineberg N, Hanley R, Baron AD: Role of amylin in insulin secretion and action in humans: antagonist studies across the spectrum of insulin sensitivity. *Diabetes Metab Res Rev* 18:118–126, 2002
87. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, Woods SC: Amylin: a novel action in the brain to reduce body weight. *Endocrinology* 141:850–853, 2000
88. Rushing PA: Central amylin signaling and the regulation of energy homeostasis. *Curr Pharm Des* 9:819–825, 2003
89. Rushing PA, Hagan MM, Seeley RJ, Lutz TA, D'Alessio DA, Air EL, Woods SC: Inhibition of central amylin signaling increases food intake and body adiposity in rats. *Endocrinology* 142:5035, 2001
90. Mulder H, Gebre-Medhin S, Betsholtz C, Sundler F, Ahren B: Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes. *Am J Physiol* 278:E684–E691, 2000
91. Mollet A, Meier S, Grabler V, Gilg S, Scharrer E, Lutz TA: Endogenous amylin contributes to the anorectic effects of cholecystokinin and bombesin. *Peptides* 24:91–98, 2003
92. Dacquin R, Davey RA, Laplace C, Levasseur R, Morris HA, Goldring SR, Gebre-Medhin S, Galson DL, Zajac JD, Karsenty G: Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo. *J Cell Biol* 164: 509–514, 2004
93. Mentlein R, Gallwitz B, Schmidt WE: Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. *Eur J Biochem* 214:829–835, 1993
94. Dupre J, Ross SA, Watson D, Brown JC: Stimulation of insulin secretion by gastric inhibitory polypeptide in man. *J Clin Endocrinol Metab* 37:826–828, 1973
95. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, Drucker DJ: International Union of Pharmacology. XXXV. The glucagon receptor family. *Pharmacol Rev* 55:167–194, 2003
96. Tseng CC, Zhang XY, Wolfe MM: Effect of GIP and GLP-1 antagonists on insulin release in the rat. *Am J Physiol* 276: E1049–E1054, 1999
97. Baggio L, Kieffer TJ, Drucker DJ: GLP-1 but not GIP regulates fasting and non-enteral glucose clearance in mice. *Endocrinology* 141:3703–3709, 2000
98. Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, Tsuda K, Hashimoto H, Yamashita T, Jomori T, Tashiro F, Miyazaki J, Seino Y: Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. *Proc Natl Acad Sci U S A* 96:14843–14847, 1999
99. Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou H, Fujimoto S, Oku A, Tsuda K, Toyokuni S, Hiai H, Mizunoya W, Fushiki T, Holst JJ, Makino M, Tashita A, Kobara Y, Tsubamoto Y, Jinnouchi T, Jomori T, Seino Y: Inhibition of gastric inhibitory polypeptide signaling prevents obesity. *Nat Med* 8:738–742, 2002
100. Gault VA, Irwin N, Green BD, McCluskey JT, Greer B, Bailey CJ, Harriott P, O'Harte FP, Flatt PR: Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. *Diabetes* 54:2436–2446, 2005
101. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. *J Clin Invest* 91:301–307, 1993
102. Meier JJ, Gallwitz B, Kask B, Deacon CF, Holst JJ, Schmidt WE, Nauck MA: Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. *Diabetes* 53 (Suppl. 3):S220–S224, 2004
103. Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA: Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. *Diabetes* 50:1004–1011, 2001
104. Dube PE, Brubaker PL: Nutrient, neural and endocrine control of glucagon-like peptide secretion. *Horm Metab Res* 36: 755–760, 2004
105. Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ: Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH₂-terminus in type 2 diabetic patients and in healthy subjects. *Diabetes* 44:1126–1131, 1995

106. Orskov C, Wettergren A, Holst JJ: Biological effects and metabolic rates of glucagon-like peptide-1 7–36 amide and glucagon-like peptide-1 7–37 in healthy subjects are indistinguishable. *Diabetes* 42:658–661, 1993
107. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA: Effects of GLP-1-(7–36)NH(2), GLP-1-(7–37), and GLP-1-(9–36)NH(2) on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. *J Clin Endocrinol Metab* 88:1772–1779, 2003
108. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CMB, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JPH, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. *Nature* 379:69–72, 1996
109. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, Denaro M: Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (*ob/ob*, *db/db*) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (*Macaca mulatta*). *Diabetes* 48:1026–1034, 1999
110. Baggio LL, Huang Q, Brown TJ, Drucker DJ: A recombinant human glucagon-like peptide (GLP)-1 albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. *Diabetes* 53:2492–2500, 2004
111. Xu G, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both β -cell replication and neogenesis, resulting in increased β -cell mass and improved glucose tolerance in diabetic rats. *Diabetes* 48:2270–2276, 1999
112. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ: Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. *J Biol Chem* 278:471–478, 2003
113. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R: Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. *Endocrinology* 144:5149–5158, 2003
114. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M: Glucagon-like peptide-1 prevents beta cell glucolipototoxicity. *Diabetologia* 47:806–815, 2004
115. MacLusky NJ, Cook S, Scrocchi L, Shin J, Kim J, Vaccarino F, Asa SL, Drucker DJ: Neuroendocrine function and response to stress in mice with complete disruption of glucagon-like peptide-1 receptor signaling. *Endocrinology* 141:752–762, 2000
116. Kinzig KP, D'Alessio DA, Seeley RJ: The diverse roles of specific GLP-1 receptors in the control of food intake and the response to visceral illness. *J Neurosci* 22:10470–10476, 2002
117. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, Greig NH: Glucagon-like peptide-1 decreases endogenous amyloid- β peptide ($A\beta$) levels and protects hippocampal neurons from death induced by $A\beta$ and iron. *J Neurosci Res* 72:603–612, 2003
118. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ, Haile CN: Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. *Nat Med* 9:1173–1179, 2003
119. Bose AK, Mocanu MM, Carr RD, Brand CL, Yellon DM: Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. *Diabetes* 54:146–151, 2005
120. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungro IN, Parker TG, Huang Q, Drucker DJ, Husain M: Cardiac function in mice lacking the glucagon-like peptide-1 receptor. *Endocrinology* 144:2242–2252, 2003
121. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, Shannon RP: Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. *Circulation* 109:962–965, 2004
122. Scrocchi LA, Brown TJ, MacLusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide receptor gene. *Nat Med* 2:1254–1258, 1996
123. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M: Exendin(9–39)amide is an antagonist of glucagon-like peptide-1(7–36)amide in humans. *J Clin Invest* 101:1421–1430, 1998
124. Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, Bloom SR: Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9–39. *Diabetes* 48:86–93, 1999
125. Schirra J, Nicolaus M, Roggel R, Katschinski M, Storr M, Woerle HJ, Goke B: Endogenous GLP-1 controls endocrine pancreatic secretion and antropyloro-duodenal motility in humans. *Gut* 28 June 2005 [Epub ahead of print]
126. Burcelin R, Da Costa A, Drucker D, Thorens B: Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide 1 receptor. *Diabetes* 50:1720–1728, 2001
127. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, Schuit FC: Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. *Virchows Arch* 438:382–387, 2001
128. Holst JJ: Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors. *Adv Exp Med Biol* 524:263–279, 2003
129. Drucker DJ: Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. *Endocrinology* 144:5145–5148, 2003
130. Drucker DJ: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. *Expert Opin Investig Drugs* 12:87–100, 2003
131. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML: Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. *Diabetes* 51:1461–1469, 2002
132. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X: Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. *Diabetologia* 42:1324–1331, 1999
133. Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA: Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide. *Metabolism* 48:385–389, 1999
134. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA: Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β -cell glucose responsiveness in VDF (*fa/fa*) Zucker rats. *Diabetes* 51:943–950, 2002
135. Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA: Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. *Diabetes* 51:2677–2683, 2002
136. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA: Dipeptidyl peptidase IV inhibitor treatment stimulates β -cell survival and islet neogenesis in streptozotocin-induced diabetic rats. *Diabetes* 52:741–750, 2003
137. Reimer MK, Holst JJ, Ahren B: Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. *Eur J Endocrinol* 146:717–727, 2002
138. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. *Proc Natl Acad Sci U S A* 97:

- 6874–6879, 2000
139. Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Yoshikawa S, Asano O, Tanaka I: Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptidyl peptidase IV-deficient Fischer rats. *Biochem Biophys Res Commun* 284:501–506, 2001
 140. Yasuda N, Nagakura T, Yamazaki K, Inoue T, Tanaka I: Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. *Life Sci* 71:227–238, 2002
 141. Conarello SL, Li Z, Ronan J, Roy RS, Zhu L, Jiang G, Liu F, Woods J, Zychband E, Moller DE, Thornberry NA, Zhang BB: Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. *Proc Natl Acad Sci U S A* 100:6825–6830, 2003
 142. Hansotia T, Baggio LL, Delmeire D, Hinke SA, Yamada Y, Tsukiyama K, Seino Y, Holst JJ, Schuit F, Drucker DJ: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. *Diabetes* 53:1326–1335, 2004
 143. Hartter E, Svoboda T, Ludvik B, Schuller M, Lell B, Kuenburg E, Brunnbauer M, Woloszczuk W, Prager R: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. *Diabetologia* 34:52–54, 1991
 144. Watschinger B, Hartter E, Traindl O, Pohanka E, Pidlich J, Kovarik J: Increased levels of plasma amylin in advanced renal failure. *Clin Nephrol* 37:131–134, 1992
 145. Sanke T, Hanabusa T, Nakano Y, Oki C, Okai K, Nishimura S, Kondo M, Nanjo K: Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. *Diabetologia* 34:129–132, 1991
 146. Kolterman OG, Gottlieb A, Moyses C, Colburn W: Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue. *Diabetes Care* 18:1179–1182, 1995
 147. Vella A, Lee JS, Camilleri M, Szarka LA, Burton DD, Zinsmeister AR, Rizza RA, Klein PD: Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus. *Neurogastroenterol Motil* 14:123–131, 2002
 148. Fineman MS, Koda JE, Shen LZ, Strobel SA, Maggs DG, Weyer C, Kolterman OG: The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. *Metabolism* 51:636–641, 2002
 149. Heise T, Heinemann L, Heller S, Weyer C, Wang Y, Strobel S, Kolterman O, Maggs D: Effect of pramlintide on symptom, catecholamine, and glucagon responses to hypoglycemia in healthy subjects. *Metabolism* 53:1227–1232, 2004
 150. Kolterman OG, Schwartz S, Corder C, Levy B, Klaff L, Peterson J, Gottlieb A: Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM. *Diabetologia* 39:492–499, 1996
 151. Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, Morgan LM, Holst JJ, Astrup A: A meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humans. *J Clin Endocrinol Metab* 86:4382–4389, 2001
 152. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellstrom PM: Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. *Br J Nutr* 91:439–446, 2004
 153. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A: The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. *Int J Obes Relat Metab Disord* 24:288–298, 2000
 154. Harder H, Nielsen L, Tu DT, Astrup A: The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. *Diabetes Care* 27:1915–1921, 2004
 155. Todd JF, Edwards CM, Gatei MA, Mather HM, Bloom SR: Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes. *Clin Sci (Lond)* 95:325–329, 1998
 156. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. *Lancet* 359:824–830, 2002
 157. Meneilly GS, Greig N, Tildesley H, Habener JF, Egan JM, Elahi D: Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. *Diabetes Care* 26:2835–2841, 2003
 158. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin 4, an exendin 3 analogue from *Heloderma suspectum* venom. *J Biol Chem* 267:7402–7405, 1992
 159. Chen YE, Drucker DJ: Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. *J Biol Chem* 272:4108–4115, 1997
 160. Nielsen LL, Young AA, Parkes DG: Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. *Regul Pept* 117:77–88, 2004
 161. Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA: Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. *Diabetologia* 48:1380–1385, 2005
 162. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, Sturis J, Hatorp V, Zdravkovic M: Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. *Diabetes Care* 25:1398–1404, 2002
 163. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. *Diabetes Care* 27:1335–1342, 2004
 164. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, Benquet C, Drucker DJ: Development and characterization of a glucagon-like peptide 1 albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. *Diabetes* 52:751–759, 2003
 165. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. *Curr Pharm Des* 7:1353–1373, 2001
 166. Chapman I, Parker B, Doran S, Feinle-Bisset C, Wishart J, Strobel S, Wang Y, Burns C, Lush C, Weyer C, Horowitz M: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. *Diabetologia* 48:838–848, 2005
 167. Thompson RG, Pearson L, Kolterman OG: Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations. *Diabetologia* 40:1278–1285, 1997
 168. Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. *Diabetes* 46:632–636, 1997
 169. Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG: Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin: the Pramlintide in Type 2 Diabetes Group. *Diabetes Care* 21:987–993, 1998

170. Whitehouse F, Kruger DF, Fineman M, Shen L, Ruggles JA, Maggs DG, Weyer C, Kolterman OG: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. *Diabetes Care* 25:724–730, 2002
171. Ratner RE, Dickey R, Fineman M, Maggs DG, Shen L, Strobel SA, Weyer C, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial. *Diabet Med* 21:1204–1212, 2004
172. Ratner RE, Want LL, Fineman MS, Velte MJ, Ruggles JA, Gottlieb A, Weyer C, Kolterman OG: Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. *Diabetes Technol Ther* 4:51–61, 2002
173. Hollander PA, Levy P, Fineman MS, Maggs DG, Shen LZ, Strobel SA, Weyer C, Kolterman OG: Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. *Diabetes Care* 26:784–790, 2003
174. Weyer C, Gottlieb A, Kim DD, Lutz K, Schwartz S, Gutierrez M, Wang Y, Ruggles JA, Kolterman OG, Maggs DG: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study. *Diabetes Care* 26:3074–3079, 2003
175. Poon T, Nelson P, Shen L, Mihm M, Taylor K, Fineman M, Kim D: Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. *Diabetes Technol Ther* 7:467–477, 2005
176. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. *Diabetes Care* 28:1092–1100, 2005
177. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. *Diabetes Care* 27:2628–2635, 2004
178. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. *Diabetes Care* 28:1083–1091, 2005
179. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. *Ann Intern Med* 143:559–569, 2005
180. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and α - and β -cell function and reduces endogenous glucose release in patients with type 2 diabetes. *Diabetes* 53:1187–1194, 2004
181. Ahren B, Gomis R, Standl E, Mills D, Schweizer A: Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. *Diabetes Care* 27:2874–2880, 2004
182. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A: Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. *J Clin Endocrinol Metab* 89:2078–2084, 2004
183. Ahren B, Pacini G, Foley JE, Schweizer A: Improved meal-related β -cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. *Diabetes Care* 28:1936–1940, 2005
184. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, Deacon CF, Holst JJ, Foley JE: Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed β -cell function in patients with type 2 diabetes. *J Clin Endocrinol Metab* 90:4888–4994, 2005
185. Patti ME, McMahon G, Mun EC, Bitton A, Holst JJ, Goldsmith J, Hanto DW, Callery M, Arky R, Nose V, Bonner-Weir S, Goldfine AB: Severe hypoglycemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. *Diabetologia* 48:2236–2240, 2005
186. Service FJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV: Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. *N Engl J Med* 353:249–254, 2005